More Women In Clinical Trials, Congress Urges FDA, NIH
This article was originally published in The Tan Sheet
Democratic and Republican female senators ask FDA for an action plan to spur greater subgroup, especially female, participation in clinical trials. A group of Democrats from the House and Senate asked GAO to examine what NIH is doing to meet the same goals.
You may also be interested in...
FDA should more strongly enforce requirements for adequate demographic subgroup representation in clinical trials for devices and other medical products, participants said at an April 1 meeting on collection and analysis of clinical trial subpopulation data to support product registration.
Advanced Imaging Group Calls For Swifter FDA Approvals For Mobile X-Ray, CT, Ultrasound Devices For COVID-19 Crisis
The Medical Imaging & Technology Alliance recently sent a letter to the US FDA recommending steps the agency can take to help the advanced imaging industry quickly respond to the COVID-19 outbreak.
FDA Open To Home COVID-19 Testing With Caveats, OIVD’s Stenzel Says; Grants First Serology Test EUA To BD
The US FDA is open to the idea of home-testing for the COVID-19 virus, but only after making sure the test is completely safe and effective, and available only through a physician’s oversight, said Tim Stenzel, director of the agency’s Office of In Vitro Diagnostics and Radiological Health. Stenzel also heralded the FDA’s first emergency use authorization for a coronavirus serology test, which was granted to diagnostic developer Becton Dickinson.